SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT02473211

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Efficacy and Safety of Sofosbuvir Plus Daclatasvir in Chinese Treatment-experienced Patients With Chronic Genotype 1b HCV Infection

For those chronic hepatitis C patients, who are interferon-ineligible or intolerant, there is a burning need for the development of pan-oral interferon-free regimen. The investigators examine the efficacy and safety of sofosbuvir, a NS5B nucleotide polymerase inhibitor and daclatasvir, an NS5A replication complex inhibitor in Chinese treatment-experienced cirrhosis patients with chronic G1b infection.

NCT02473211 Chronic Hepatitis C Infection
MeSH:Infection Hepatitis C Hepatitis C, Chronic

2 Interventions

Name: Sofosbuvir

Description: Sofosbuvir 400 mg tablet administered once daily
Type: Drug
Group Labels: 1


Name: Daclatasvir

Description: Daclatasvir 60mg tablet administered once daily
Type: Drug
Group Labels: 1


Primary Outcomes

Description: SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ) (15 IU/ml) 12 weeks following the last dose of study drug

Measure: Proportion of participants with sustained virologic response 12 weeks after the end of treatment (SVR12)

Time: Post treatment Week 12

Purpose: Treatment

Allocation: N/A

Single Group Assignment

There is one SNP


1 rs12979860

At baseline, liver stiffness measurement (LSM) using transient elastography (FibroScan®) is used to assess liver fibrosis and the single nucleotide polymorphism ofinterferon-λ 3 (IL-28, rs12979860, C or T) and IFLN4 (ss469415590, TT or ΔG) is determined.

HPO Nodes